New patent for the Boehringer Ingelheim drug TRIJARDY XR – DrugPatentWatch
Expiration of Annual Drug Patent for TRIJARDY+XR
Trijardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from a single supplier. There are fifteen patents protecting this drug.
TRIJARDY XR drug price trends.
Drug patent litigation for TRIJARDY XR.
This drug has four hundred and forty-eight patent family members in forty-eight countries.
The generic ingredients in TRIJARDY XR are empagliflozin; linagliptin; metformin hydrochloride. One registered supplier for this compound. Additional details are available on empagliflozin; linagliptin; metformin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in New patent for the Boehringer Ingelheim drug TRIJARDY XR
